Presented at the Irish Association for Cancer Research (IACR) Conference 2025
Background
Ovarian cancer (OC) is the fifth leading cause of cancer deaths in women worldwide. Sacituzumab govitecan (SG) is an antibody-drug conjugate (ADC) targeting TROP2. SG contains SN-38, a topoisomerase I inhibitor, as a cytotoxic agent. TROP2 is commonly overexpressed in OC, making it an attractive therapeutic target. Talazoparib is a Poly-(ADP-ribose) polymerase (PARP) inhibitor. SG and talazoparib are each approved for the treatment of several cancer types. This pre-clinical study investigated the activity of SG + talazoparib in OC cell line models in adherent and 3D bioprinted conditions.
